Tag: TRUST-II trial

Home / TRUST-II trial

Categories

Taletrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer

On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a type of medicine that blocks certain enzymes, for people with advanced or spreading ROS1-posit...
trust-ii-trial

Scan the code